Drug details

Tibsovo (ivosidenib tablets)

type of IDH1 Inhibitors

Tibsovo (ivosidenib tablets) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• itching
• fainting,
• weakness,
• painful urination,
• fast or irregular heartbeat,
• rash, and
• change in the amount of urine,
• muscle or joint pain,
• muscle spasms,
• severe dizziness,
• low back or side pain,
• numbness or tingling skin,
• pain or bloody urine,

The following drugs are related to Tibsovo, either as a replacement or used together:

• Bosulif (bosutinib tablets)
• Sprycel (dasatinib)
• Daurismo (glasdegib tablets)
• Xospata (gilteritinib tablets)
• Gleevec (imatinib mesylate)
• Iclusig (ponatinib tablets)
• Tasigna Capsules (nilotinib capsules)